BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc. as CFO on Jan. 25. Frates said he felt a “calling” to do more to combat amyotrophic lateral sclerosis after his cousin...
BioCentury | Dec 5, 2020
Product Development

The vaccine is here. Three questions about what happens next

The COVID-19 vaccine rollout is starting in the U.K., and is on the doorstep in the U.S. and Europe, building to a collective huge sigh of relief. The efficacy, at least for the first two,...
BioCentury | Nov 28, 2020
Product Development

U.S., U.K. volume bets on AZD1222 come into question with vaccine efficacy data

As the U.K. moves to review AZD1222 from AstraZeneca and Oxford, efficacy data from the three front-runner COVID-19 vaccines provides an opportunity to take stock of governments’ bets on which candidates warranted the most investment,...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

Icahn researchers identify autoantibodies in COVID-19-recovered childrenIcahn School of Medicine at Mount Sinai researchers published in Cell the immune profiles of nine COVID-19-recovered children with...
BioCentury | Aug 28, 2020

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

This story was updated to correct the nature of Imperial College's deal with the U.K. As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi...
BioCentury | Jul 21, 2020
Product Development

As U.K. secures access to two more vaccines, task force Chair Bingham says more to come

U.K. Vaccine Taskforce Chair Kate Bingham says supply agreements for U.K. access to COVID-19 vaccines from Valneva and partners BioNTech and Pfizer and are the first of up to eight vaccine deals expected in the...
BioCentury | Jul 11, 2020
Translation in Brief

Peptide blocker of myeloid checkpoint; plus a magnet-based device to collect circulating tumor cells, severe vs. mild COVID-19 immune cell profiles and more

Macrocyclic don’t-eat-me signal blocker A Japan-based team has reported in Cell Chemical Biology the development of a macrocyclic peptide that allosterically blocks the CD47-SIRPA myeloid checkpoint. The 15-residue peptide binds mouse SIRPA, and in a...
Items per page:
1 - 10 of 822